NCT01041625View on ClinicalTrials.gov

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Lichen Planus
Interventions
DRUG

Apremilast (CC-10004)

Apremilast 20 mg tablet PO administered BID over 12 weeks

Trial Locations (1)

23507

Virginia Clinical Research Inc., Norfolk

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Virginia Clinical Research, Inc.

OTHER